Pharmaceutical Research

, 36:39 | Cite as

Knockdown of Orphan Transporter SLC22A18 Impairs Lipid Metabolism and Increases Invasiveness of HepG2 Cells

  • Shingo Ito
  • Gentaro Honda
  • Yu Fujino
  • Seiryo Ogata
  • Mio Hirayama-Kurogi
  • Sumio OhtsukiEmail author
Research Paper



The aim of this work is to investigate the roles of solute carrier family 22 member 18 (SLC22A18) in lipid metabolism and in establishing the tumor phenotype of HepG2 cells.


SLC22A18-knockdown HepG2 cells were established by stable transfection with shRNA. Protein expression levels were measured by quantitative proteomics and Western blot analysis. Cell growth was examined by cell counting kit. Accumulation of triglyceride-rich lipid droplets was measured by Oil-Red O staining. Cell migration and invasion were examined by Transwell assays.


SLC22A18-knockdown HepG2 cells accumulated triglyceride-rich lipid droplets and showed decreased expression levels of lysosomal/autophagic proteins, suggesting that lipid degradation is suppressed. Growth of HepG2 cells was decreased by SLC22A18 knockdown, but was restored by free fatty acid supplementation. In addition, SLC22A18 knockdown decreased the expression of insulin-like growth factor-binding protein 1 (IGFBP-1) and increased the invasion ability of HepG2 cells. Exogenous IGFBP-1 blocked the increase of invasion activity induced by SLC22A18 knockdown.


Our results suggest that suppression of SLC22A18 decreased the supply of intracellular free fatty acids from triglyceride-rich lipid droplets by impairing the lysosomal/autophagy degradation pathway and reduced the invasive activity of HepG2 cells by decreasing IGFBP-1 expression.


fatty acid IGFBP-1 orphan transporter quantitative proteomics SLC22A18 



Chemically defined


Free fatty acids


Hepatocellular carcinomas


Insulin-like growth factor-binding protein-1


KQT-like subfamily Q, member1


Non-alcoholic fatty liver disease


Short hairpin RNA


Solute carrier family 22 member 18




Type 2 diabetes mellitus



We are grateful for partial financial support through three Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science (JSPS) for Research Activity Start-up (No. 24890170), Young Scientific Research (B) (No. 26860109) and Scientific Research (C) (No. 16 K08373), as well as a grant from the Takeda Science Foundation. S. Ohtsuki is a full professor at Kumamoto University and is also a director of Proteomedix Frontiers. This study was not supported by the company, and its position at the company did not influence the design of the study, the collection of the data, the analysis or interpretation of the data, the decision to submit the manuscript for publication, or the writing of the manuscript and did not present any financial conflicts. The other authors declare no competing interests.

Authorship Contributions

S. Ito, G. Honda. and S. Ohtsuki contributed to the study design. S. Ito, G.Honda, Y. Fujino, S. Ogata, M. Hirayama-kurogi and S.Ohtsuki conducted experiments and performed data analysis. S. Ito and S. Ohtsuki wrote the manuscript. All authors gave final approval for the manuscript to be published.

Supplementary material

11095_2018_2565_MOESM1_ESM.docx (160 kb)
ESM 1 (DOCX 160 kb)


  1. 1.
    Chu SH, Ma YB, Feng DF, Li ZQ, Jiang PC. Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. J Transl Med. 2013;11:69.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, et al. Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 2012;19(1):95–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Gallagher E, Mc Goldrick A, Chung WY, Mc Cormack O, Harrison M, Kerin M, et al. Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer. Genomics. 2006;88(1):12–7.PubMedCrossRefGoogle Scholar
  4. 4.
    He H, Xu C, Zhao Z, Qin X, Xu H, Zhang H. Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery. Cancer Epidemiol. 2011;35(3):279–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Schwienbacher C, Sabbioni S, Campi M, Veronese A, Bernardi G, Menegatti A, et al. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci U S A. 1998;95(7):3873–8.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L, et al. Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci U S A. 2000;97(10):5445–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Jung Y, Jun Y, Lee HY, Kim S, Jung Y, Keum J, et al. Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer. Oncotarget. 2015;6(28):25368–80.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406.PubMedCrossRefGoogle Scholar
  9. 9.
    Dao D, Frank D, Qian N, O'Keefe D, Vosatka RJ, Walsh CP, et al. IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet. 1998;7(4):597–608.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakamura K, Hirayama-Kurogi M, Ito S, Kuno T, Yoneyama T, Obuchi W, et al. Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: comparison with MRM/SRM and HR-MRM/PRM. Proteomics. 2016;16(15–16):2106–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Albrecht S, Hartmann W, Houshdaran F, Koch A, Gartner B, Prawitt D, et al. Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma. Int J Cancer. 2004;111(4):627–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing. Oncogene. 2014;33(39):4786–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamamoto T, Izumi-Yamamoto K, Iizuka Y, Shirota M, Nagase M, Fujita T, et al. A novel link between Slc22a18 and fat accumulation revealed by a mutation in the spontaneously hypertensive rat. Biochem Biophys Res Commun. 2013;440(4):521–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet. 2008;40(9):1092–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, et al. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic beta-cell mass by epigenetic modification of Cdkn1c. Proc Natl Acad Sci U S A. 2015;112(27):8332–7.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Ito S, Fujino Y, Ogata S, Hirayama-Kurogi M, Ohtsuki S. Involvement of an orphan transporter, SLC22A18, in cell growth and drug resistance of human breast Cancer MCF7 cells. J Pharm Sci. 2018;107(12):3163–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang WL, Wei L, Huang WQ, Li R, Shen WY, Liu JY, et al. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth. Oncol Rep. 2014;31(5):2328–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhang H, Chen W, Fu X, Su X, Yang A. CBX3 promotes tumor proliferation by regulating G1/S phase via p21 downregulation and associates with poor prognosis in tongue squamous cell carcinoma. Gene. 2018;654:49–56.PubMedCrossRefGoogle Scholar
  19. 19.
    Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basanez G, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008;68(13):5246–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Wu XS, Bao TH, Ke Y, Sun DY, Shi ZT, Tang HR, et al. Hint1 suppresses migration and invasion of hepatocellular carcinoma cells in vitro by modulating girdin activity. Tumour Biol. 2016;37(11):14711–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Dai B, Ruan B, Wu J, Wang JL, Shang RZ, Sun W, et al. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7(9):5645–54.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhu WL, Fan BL, Liu DL, Zhu WX. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res. 2009;29(7):2531–4.PubMedGoogle Scholar
  23. 23.
    Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, et al. Italian liver Cancer G. determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer. 2014;120(14):2150–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y, et al. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver. 2012;32(9):1382–90.CrossRefGoogle Scholar
  25. 25.
    Kondoh N, Imazeki N, Arai M, Hada A, Hatsuse K, Matsuo H, et al. Activation of a system a amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol. 2007;31(1):81–7.PubMedGoogle Scholar
  26. 26.
    Yao HR, Liu J, Plumeri D, Cao YB, He T, Lin L, et al. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res. 2011;3(3):284–91.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ. 2013;20(1):3–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720–8.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogene. 2016;5:e189.CrossRefGoogle Scholar
  30. 30.
    Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature. 2009;458(7242):1131–5.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (Baltimore Md). 2010;51(2):679–89.CrossRefGoogle Scholar
  32. 32.
    Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010;11(6):467–78.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Tatsumi T, Takayama K, Ishii S, Yamamoto A, Hara T, Minami N, et al. Forced lipophagy reveals that lipid droplets are required for early embryonic development in mouse. Development (Cambridge, England). 2018;145(4):dev161893.CrossRefGoogle Scholar
  34. 34.
    Lam T, Harmancey R, Vasquez H, Gilbert B, Patel N, Hariharan V, et al. Reversal of intramyocellular lipid accumulation by lipophagy and a p62-mediated pathway. Cell Death Discov. 2016;2:16061.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Lei T, Ling X. IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. World J Gastroenterol. 2015;21(35):10137–49.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Jia S, Du Z, Jiang H, Huang X, Chen Z, Chen N. Daintain/AIF-1 accelerates the activation of insulin-like growth factor-1 receptor signaling pathway in HepG2 cells. Oncol Rep. 2015;34(1):511–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533–9.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Yang J, Waldron RT, Su HY, Moro A, Chang HH, Eibl G, et al. Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2016;311(4):G675–87.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Feng C, Li D, Jiang L, Liu X, Li Q, Geng C, et al. Citreoviridin induces triglyceride accumulation in hepatocytes through inhibiting PPAR-alpha in vivo and in vitro. Chem Biol Interact. 2017;273:212–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996;1302(2):93–109.PubMedCrossRefGoogle Scholar
  41. 41.
    Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J. 2014;13:17.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–33.PubMedCrossRefGoogle Scholar
  43. 43.
    Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J Biol Chem. 2006;281(51):39607–19.PubMedCrossRefGoogle Scholar
  44. 44.
    Reece M, Prawitt D, Landers J, Kast C, Gros P, Housman D, et al. Functional characterization of ORCTL2 - an organic cation transporter expressed in the renal proximal tubules. FEBS Lett. 1998;433(3):245–50.PubMedCrossRefGoogle Scholar
  45. 45.
    Yamada HY, Gorbsky GJ. Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105. Oncogene. 2006;25(9):1330–9.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Microbiology, Faculty of Life SciencesKumamoto UniversityKumamotoJapan
  2. 2.Department of Pharmaceutical Microbiology, School of PharmacyKumamoto UniversityKumamotoJapan
  3. 3.Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical SciencesKumamoto UniversityKumamotoJapan
  4. 4.AMED-CREST, Japan Agency for Medical Research and DevelopmentTokyoJapan

Personalised recommendations